Presentation will include full data from the six-month interim timepoint from the cohort of the first 100 patients randomized in study 014/015, a Phase II trial evaluating evenamide as add-on therapy
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): ConferenceNewron to present at the 31st European Congress of Psychiatry 17.03.2023 / 07:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Newron to present at the 31st European Congress of PsychiatryPresentation will include ful.
Ad hoc announcement pursuant to Art. 53 LR Newron Pharmaceuticals S.p.A. ("Newron") (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients
The Berlin Museum of Islamic Art’s new online portal is the first digital platform in the German-speaking world to present Islamic cultures in an innovative and entertaining way. By Ceyda Nurtsch